Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Liberty Live-C
LLYVK
5
American Express
AXP
US OptionsDetailed Quotes
PTCT250516P50000
- 0.00
- 0.000.00%
15min DelayClose May 7 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest50.00Strike Price0.00Turnover0.00%IV-22.67%PremiumMay 16, 2025Expiry Date9.24Intrinsic Value100Multiplier9DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma4.50Leverage Ratio--Theta--Rho--Eff Leverage--Vega
PTC Therapeutics Stock Discussion
Sign in to post a comment
The S&P 500 snapped its longest winning streak in 20 years on Monday as markets inched lower amid little significant tariff news coupled with caution ahead of the Federal Reserve's rate decision due out Wednesday.
The $S&P 500 Index (.SPX.US)$ shed 36.29 points (0.6%) to close at 5,650.38, halting a run of consecutive positive sessions at nine – the index's longest winning streak since 2004.
The $Nasdaq Composite Index (.IXIC.US)$ likewise ...
The $S&P 500 Index (.SPX.US)$ shed 36.29 points (0.6%) to close at 5,650.38, halting a run of consecutive positive sessions at nine – the index's longest winning streak since 2004.
The $Nasdaq Composite Index (.IXIC.US)$ likewise ...
11
2
4
$PTC Therapeutics (PTCT.US)$
Breakthrough: PTC518 Shows 39% HTT Reduction in Huntington's Disease Trial, Potential First Disease-Modifying Treatment
Breakthrough: PTC518 Shows 39% HTT Reduction in Huntington's Disease Trial, Potential First Disease-Modifying Treatment
$PTC Therapeutics (PTCT.US)$
Breakthrough PKU Treatment Enables 126% Higher Protein Intake in Clinical Trial
Breakthrough PKU Treatment Enables 126% Higher Protein Intake in Clinical Trial
$PTC Therapeutics (PTCT.US)$
Could This Rare Disease Drug Be PTC's Next Breakthrough? FDA Priority Review Reveals Major Potential
Could This Rare Disease Drug Be PTC's Next Breakthrough? FDA Priority Review Reveals Major Potential
$PTC Therapeutics (PTCT.US)$
PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia
12/19/2024 08:00AM ET
- If approved, vatiquinone would be the first and only authorized therapy for children with FA -
- PTC's fourth approval application submitted to FDA in 2024 -
WARREN, N.J., Dec. 19, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today the submission of the vatiquinone New Drug Application (NDA) ...
PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia
12/19/2024 08:00AM ET
- If approved, vatiquinone would be the first and only authorized therapy for children with FA -
- PTC's fourth approval application submitted to FDA in 2024 -
WARREN, N.J., Dec. 19, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today the submission of the vatiquinone New Drug Application (NDA) ...
🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
20
3
3
$PTC Therapeutics (PTCT.US)$ just dud offering 22.87 a share get out 🔻🔻🔻🔻
PTC Therapeutics' low P/S ratio is seen as reasonable due to industry underperformance. However, weak revenue outlook is pressuring shares, making maintaining current prices challenging. Shareholders accept the low P/S, expecting no future revenue surprises.
Recent insider selling at PTC Therapeutics outweighs insider buying, a potential bearish sign. Despite some insider buying, the long-term outlook lacks positivity. Insider ownership suggests alignment with shareholders, but insider selling warrants caution.
1
PTC Therapeutics' ongoing losses may have led to negative market view, causing a contradictory movement in the stock against the company’s revenue growth. The firm's underperformance in the past five years suggests unresolved issues. Currently, the healthcare company has five investment analysis warning signs.
No comment yet
Market Insights
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
Unlock Now
Discussing
Berkshire 2025 highlights: Stepping aside as CEO, trade and market volatility
$Berkshire Hathaway-A (BRK.A.US)$ held its highly anticipated annual shareholders meeting Saturday. Here are some key takeaways from the eve
Buffettttttt
May 3 21:00
Berkshire's 2025 Annual Shareholders Meeting
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
73685167 : .
74377323 : $NVIDIA (NVDA.US)$